<?xml version="1.0" encoding="UTF-8"?>
<p>All the molecular modelling simulations were performed using Molecular Operating Environment (MOE, 2010.10) software. All minimizations were carried out with MOE until an RMSD gradient of 0.05 kcal·mol
 <sup>−1 </sup>Å
 <sup>−1</sup> with MMFF94× force field and the partial charges were automatically calculated. The X-ray crystallographic structure of CDK2 co-crystallized with an oxindole derivative (IC
 <sub>50</sub> = 60 nM) as inhibitor (PDB ID: 1FVT)
 <xref rid="CIT0109" ref-type="bibr">
  <sup>109</sup>
 </xref> and of GSK-3β co-crystallized with the oxindole derivative Indirubin-3′-monoxime (IC
 <sub>50</sub> = 22 nM) as inhibitor (PDB ID: 1Q41)
 <xref rid="CIT0110" ref-type="bibr">
  <sup>110</sup>
 </xref> were downloaded from the protein data bank
 <xref rid="CIT0120" ref-type="bibr">
  <sup>120</sup>
 </xref>. The selection of these two protein structures specifically attributed to their co-crystallization with potent CDK2 and GSK-3β oxindole-based inhibitors, respectively.
</p>
